Department of Radiation Oncology and Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Clin Cancer Res. 2011 Jul 1;17(13):4192-9. doi: 10.1158/1078-0432.CCR-10-2760. Epub 2011 May 16.
The past decade has seen significant breakthroughs in our knowledge of the tumor biology of non-small cell lung cancer (NSCLC). Signaling pathways that are vital for tumor growth have been identified and have been effectively targeted for pharmacologic intervention. Furthermore, advances in imaging and treatment delivery have allowed radiation oncologists to deliver therapy more precisely to mobile tumors, while minimizing the dose to surrounding critical structures. This article summarizes the implications of these advances for the patient with unresectable locally advanced NSCLC and highlights ongoing work to improve clinical outcomes in this disease.
在过去的十年中，我们对非小细胞肺癌（NSCLC）的肿瘤生物学有了重大的认识突破。已经确定了对肿瘤生长至关重要的信号通路，并已有效地针对这些通路进行药物干预。此外，影像学和治疗方法的进步使放射肿瘤学家能够更精确地将治疗方法应用于移动肿瘤，同时将周围关键结构的剂量降至最低。本文总结了这些进展对不可切除的局部晚期 NSCLC 患者的影响，并强调了在该疾病中改善临床结果的持续工作。
